Recently, university-industry collaboration has become more popular in the discovery and development of new medicines. However, the effective management of such collaboration has not been thoroughly investigated. In this study, we thoroughly examined research management in the discovery process of Actemra, the first Japan-oriented therapeutic monoclonal antibody produced through collaborative research between Chugai Pharmaceuticals and Osaka University. Our analysis demonstrates that the accumulation of internal research capability is effective in sensing superior partners in university-industry collaboration. It improves the ability to determine suitable collaborators and increases the industry’s opportunity to be chosen as a partner by excellent academic laboratories. In addition, Chugai Pharmaceuticals and Osaka University separately conducted their research for each own purpose, and connected sparsely only by exchanging each knowledge and findings. This unique research management enabled Chugai Pharmaceuticals to focus on and expand its own drug discovery effort with quick acquisition of up-to-date findings and technologies acquired from basic science research by Osaka University, leading to the creation of innovative medicines.
各種検索
サポート
ヘルプ